{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T09:35:52Z","timestamp":1768037752524,"version":"3.49.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T00:00:00Z","timestamp":1547683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2016JJ4068"],"award-info":[{"award-number":["2016JJ4068"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009377","name":"Education Department of Hunan Province","doi-asserted-by":"publisher","award":["16A160"],"award-info":[{"award-number":["16A160"]}],"id":[{"id":"10.13039\/100009377","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00059-018-4779-y","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T14:11:26Z","timestamp":1547734286000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a\u00a0systematic review and meta-analysis of randomized controlled trials","Pr\u00e4ventive Anwendung von Carvedilol bei Anthrazyklin-induzierter Kardiotoxizit\u00e4t: systematische \u00dcbersicht und Metaanalyse randomisierter kontrollierter Studien"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6954-8881","authenticated-orcid":false,"given":"T.","family":"Zhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Daniyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1592-660X","authenticated-orcid":false,"given":"Y.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,17]]},"reference":[{"issue":"4","key":"4779_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","volume":"15","author":"WJ Gradishar","year":"2017","unstructured":"Gradishar WJ, Anderson BO, Balassanian R et al (2017) NCCN guidelines insights: breast cancer, version 1.2017. J\u00a0Natl Compr Canc Netw 15(4):433\u2013451","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"1","key":"4779_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00280-016-3070-2","volume":"78","author":"M Ogura","year":"2016","unstructured":"Ogura M, Ishida T, Tsukasaki K et al (2016) Effects of first-line chemotherapy on natural killer cells in adult T\u2011cell leukemia-lymphoma and peripheral T\u2011cell lymphoma. Cancer Chemother Pharmacol 78(1):199\u2013207. https:\/\/doi.org\/10.1007\/s00280-016-3070-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"4779_CR3","doi-asserted-by":"publisher","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","volume":"15","author":"RT Hoppe","year":"2017","unstructured":"Hoppe RT, Advani RH, Ai WZ et al (2017) Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(5):608\u2013638","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"9","key":"4779_CR4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","volume":"14","author":"SM Horwitz","year":"2016","unstructured":"Horwitz SM, Zelenetz AD, Gordon LI et al (2016) NCCN guidelines insights: non-Hodgkin\u2019s lymphomas, version 3.2016. J Natl Compr Canc Netw 14(9):1067\u20131079","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"11","key":"4779_CR5","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","volume":"97","author":"SM Swain","year":"2003","unstructured":"Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a\u00a0retrospective analysis of three trials. Cancer 97(11):2869\u20132879. https:\/\/doi.org\/10.1002\/cncr.11407","journal-title":"Cancer"},{"issue":"8","key":"4779_CR6","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1161\/01.cir.0000085166.44904.79","volume":"108","author":"TJ Wang","year":"2003","unstructured":"Wang TJ, Evans JC, Benjamin EJ et al (2003) Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108(8):977\u2013982. https:\/\/doi.org\/10.1161\/01.cir.0000085166.44904.79","journal-title":"Circulation"},{"issue":"6","key":"4779_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/annonc\/mdf167","volume":"13","author":"LC Kremer","year":"2002","unstructured":"Kremer LC, van der Pal HJ, Offringa M et al (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a\u00a0systematic review. Ann Oncol 13(6):819\u2013829","journal-title":"Ann Oncol"},{"issue":"18","key":"4779_CR8","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1016\/j.ejca.2006.08.005","volume":"42","author":"EC van Dalen","year":"2006","unstructured":"van Dalen EC, van der Pal HJ, Kok WE et al (2006) Clinical heart failure in a\u00a0cohort of children treated with anthracyclines: a\u00a0long-term follow-up study. Eur J Cancer 42(18):3191\u20133198. https:\/\/doi.org\/10.1016\/j.ejca\u00a0.2006.08.005","journal-title":"Eur J Cancer"},{"key":"4779_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2017-312103","author":"PA Henriksen","year":"2017","unstructured":"Henriksen PA (2017) Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. https:\/\/doi.org\/10.1136\/heartjnl-2017-312103","journal-title":"Heart"},{"key":"4779_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003917.pub4","author":"EC van Dalen","year":"2011","unstructured":"van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD003917.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"1081","key":"4779_CR11","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/postgradmedj-2015-133535","volume":"91","author":"S Yun","year":"2015","unstructured":"Yun S, Vincelette ND, Abraham I (2015) Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a\u00a0systematic review and meta-analysis. Postgrad Med\u00a0J 91(1081):627\u2013633. https:\/\/doi.org\/10.1136\/postgradmedj-2015-133535","journal-title":"Postgrad Med J"},{"issue":"2","key":"4779_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1527-3466.2001.tb00061.x","volume":"19","author":"J Cheng","year":"2001","unstructured":"Cheng J, Kamiya K, Kodama I (2001) Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 19(2):152\u2013171","journal-title":"Cardiovasc Drug Rev"},{"issue":"4","key":"4779_CR13","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.yjmcc.2004.05.024","volume":"37","author":"P Spallarossa","year":"2004","unstructured":"Spallarossa P, Garibaldi S, Altieri P et al (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J\u00a0Mol Cell Cardiol 37(4):837\u2013846. https:\/\/doi.org\/10.1016\/j.yjmcc.2004.05.024","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"4779_CR14","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1124\/jpet.115.225375","volume":"355","author":"YL Chen","year":"2015","unstructured":"Chen YL, Chung SY, Chai HT et al (2015) Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy. J\u00a0Pharmacol Exp Ther 355(3):516\u2013527. https:\/\/doi.org\/10.1124\/jpet.115.225375","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20133","key":"4779_CR15","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tox.2010.05.003","volume":"274","author":"W Arozal","year":"2010","unstructured":"Arozal W, Watanabe K, Veeraveedu PT et al (2010) Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274(1\u20133):18\u201326. https:\/\/doi.org\/10.1016\/j.tox.2010.05.003","journal-title":"Toxicology"},{"key":"4779_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008011.pub3","author":"DK Cheuk","year":"2016","unstructured":"Cheuk DK, Sieswerda E, van Dalen EC et al (2016) Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008011.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"4779_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv357","author":"F Shaikh","year":"2016","unstructured":"Shaikh F, Dupuis LL, Alexander S et al (2016) Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and Meta-analysis. J\u00a0Natl Cancer Inst 108(4). https:\/\/doi.org\/10.1093\/jnci\/djv357","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"4779_CR18","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/annonc\/mdw671","volume":"28","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ong G, Fazelzad R et al (2017) Interventions for preventing cardiomyopathy due to anthracyclines: a\u00a0Bayesian network meta-analysis. Ann Oncol 28(3):628\u2013633. https:\/\/doi.org\/10.1093\/annonc\/mdw671","journal-title":"Ann Oncol"},{"issue":"1","key":"4779_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13643-017-0663-8","volume":"6","author":"MJ Page","year":"2017","unstructured":"Page MJ, Moher D (2017) Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and Meta-analyses (PRISMA) statement and extensions: a\u00a0scoping review. Syst Rev 6(1):263. https:\/\/doi.org\/10.1186\/s13643-017-0663-8","journal-title":"Syst Rev"},{"key":"4779_CR20","volume-title":"Cochrane Handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration","author":"JPGS Higgins","year":"2011","unstructured":"Higgins JPGS (2011) Cochrane Handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration (http:\/\/ www.cochrane-handbook.org.)"},{"issue":"2","key":"4779_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2522\/ptj.20070147","volume":"88","author":"SA Olivo","year":"2008","unstructured":"Olivo SA, Macedo LG, Gadotti IC et al (2008) Scales to assess the quality of randomized controlled trials: a\u00a0systematic review. Phys Ther 88(2):156\u2013175. https:\/\/doi.org\/10.2522\/ptj.20070147","journal-title":"Phys Ther"},{"issue":"1","key":"4779_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1\u201312","journal-title":"Control Clin Trials"},{"issue":"5","key":"4779_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/fjc.0000000000000470","volume":"69","author":"M Nabati","year":"2017","unstructured":"Nabati M, Janbabai G, Baghyari S et al (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J\u00a0Cardiovasc Pharmacol 69(5):279\u2013285. https:\/\/doi.org\/10.1097\/fjc.0000000000000470","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"4779_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12872-016-0364-6","volume":"16","author":"SH Armenian","year":"2016","unstructured":"Armenian SH, Hudson MM, Chen MH et al (2016) Rationale and design of the Children\u2019s Oncology Group (COG) study ALTE1621: a\u00a0randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. BMC Cardiovasc Disord 16(1):187. https:\/\/doi.org\/10.1186\/s12872-016-0364-6","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"4779_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","volume":"55","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J\u00a0Am Coll Cardiol 55(3):213\u2013220. https:\/\/doi.org\/10.1016\/j.jacc.2009.03.095","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"4779_CR26","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","volume":"61","author":"X Bosch","year":"2013","unstructured":"Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J\u00a0Am Coll Cardiol 61(23):2355\u20132362. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.072","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"4779_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5603\/CJ.a2013.0150","volume":"21","author":"A Elitok","year":"2014","unstructured":"Elitok A, Oz F, Cizgici AY et al (2014) Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol\u00a0J 21(5):509\u2013515. https:\/\/doi.org\/10.5603\/CJ.a2013.0150","journal-title":"Cardiol J"},{"issue":"8","key":"4779_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.cardfail.2012.06.416","volume":"18","author":"NA El-Shitany","year":"2012","unstructured":"El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE (2012) Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J\u00a0Card Fail 18(8):607\u2013613. https:\/\/doi.org\/10.1016\/j.cardfail.2012.06.416","journal-title":"J Card Fail"},{"issue":"5","key":"4779_CR29","doi-asserted-by":"publisher","first-page":"725","DOI":"10.4103\/ijmr.IJMR_1323_14","volume":"144","author":"R Jhorawat","year":"2016","unstructured":"Jhorawat R, Kumari S, Varma SC et al (2016) Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian J Med Res 144(5):725\u2013729. https:\/\/doi.org\/10.4103\/ijmr.IJMR_1323_14","journal-title":"Indian J Med Res"},{"issue":"11","key":"4779_CR30","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","volume":"48","author":"N Kalay","year":"2006","unstructured":"Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J\u00a0Am Coll Cardiol 48(11):2258\u20132262. https:\/\/doi.org\/10.1016\/j.jacc.2006.07.052","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"4779_CR31","first-page":"936","volume":"35","author":"L Liu","year":"2013","unstructured":"Liu L, Liu ZZ, Liu YY et al (2013) Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer. Zhonghua Zhong Liu Za Zhi 35(12):936\u2013940","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"4779_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000442722","volume":"134","author":"A Tashakori Beheshti","year":"2016","unstructured":"Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G et al (2016) Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology 134(1):47\u201353. https:\/\/doi.org\/10.1159\/000442722","journal-title":"Cardiology"},{"key":"4779_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.049","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley JMR et al (2018) Carvedilol for prevention of chemotherapy related cardiotoxicity. J\u00a0Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"4779_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00059-011-3452-5","volume":"36","author":"M Noutsias","year":"2011","unstructured":"Noutsias M, Maisch B (2011) Treatment of cardiovascular diseases in cancer patients. Herz 36(4):340\u2013345. https:\/\/doi.org\/10.1007\/s00059-011-3452-5","journal-title":"Herz"},{"issue":"15","key":"4779_CR35","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/eurheartj\/ehs181","volume":"34","author":"TM Suter","year":"2013","unstructured":"Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart\u00a0J 34(15):1102\u20131111. https:\/\/doi.org\/10.1093\/eurheartj\/ehs181","journal-title":"Eur Heart J"},{"key":"4779_CR36","doi-asserted-by":"publisher","DOI":"10.1097\/HCO.0000000000000145","author":"CB Johnson","year":"2015","unstructured":"Johnson CB, Sulpher J, Stadnick E (2015) Evaluation, prevention and management of cancer therapy-induced cardiotoxicity: a\u00a0contemporary approach for clinicians. Curr Opin Cardiol. https:\/\/doi.org\/10.1097\/HCO.0000000000000145","journal-title":"Curr Opin Cardiol"},{"issue":"9","key":"4779_CR37","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1056\/NEJMoa1510795","volume":"374","author":"GT Armstrong","year":"2016","unstructured":"Armstrong GT, Chen Y, Yasui Y et al (2016) Reduction in late mortality among 5\u2011year survivors of childhood cancer. N\u00a0Engl J Med 374(9):833\u2013842. https:\/\/doi.org\/10.1056\/NEJMoa1510795","journal-title":"N Engl J Med"},{"issue":"3","key":"4779_CR38","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik JL, Byers T, DiGuiseppi C et al (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a\u00a0retrospective cohort study. Breast Cancer Res 13(3):R64. https:\/\/doi.org\/10.1186\/bcr2901","journal-title":"Breast Cancer Res"},{"issue":"3","key":"4779_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-016-3781-4","volume":"156","author":"G Murtagh","year":"2016","unstructured":"Murtagh G, Lyons T, O\u2019Connell E et al (2016) Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Breast Cancer Res Treat 156(3):501\u2013506. https:\/\/doi.org\/10.1007\/s10549-016-3781-4","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"4779_CR40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ehf2.12153","volume":"4","author":"A Cohen-Solal","year":"2017","unstructured":"Cohen-Solal A, Jacobson AF, Pina IL (2017) Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Fail 4(4):499\u2013506. https:\/\/doi.org\/10.1002\/ehf2.12153","journal-title":"ESC Heart Fail"},{"key":"4779_CR41","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X14666180123164916","author":"C Inampudi","year":"2018","unstructured":"Inampudi C, Alvarez P, Asleh R, Briasoulis A (2018) Therapeutic approach to patients with heart failure with reduced ejection fraction and end-stage renal disease. Curr Cardiol Rev. https:\/\/doi.org\/10.2174\/1573403X14666180123164916","journal-title":"Curr Cardiol Rev"},{"key":"4779_CR42","doi-asserted-by":"publisher","DOI":"10.2174\/1381612824666180111105923","author":"C Guang-Yi","year":"2018","unstructured":"Guang-Yi C, Li-Sha G, Yue-Chun L (2018) Role of heart rate reduction in the management of myocarditis. Curr Pharm Des. https:\/\/doi.org\/10.2174\/1381612824666180111105923","journal-title":"Curr Pharm Des"},{"issue":"9128","key":"4779_CR43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/s0140-6736(98)01085-x","volume":"352","author":"D Moher","year":"1998","unstructured":"Moher D, Pham B, Jones A et al (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352(9128):609\u2013613. https:\/\/doi.org\/10.1016\/s0140-6736(98)01085-x","journal-title":"Lancet"},{"issue":"9","key":"4779_CR44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","volume":"27","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a\u00a0report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J\u00a0Am Soc Echocardiogr 27(9):911\u2013939. https:\/\/doi.org\/10.1016\/j.echo.2014.07.012","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"4779_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","volume":"61","author":"P Thavendiranathan","year":"2013","unstructured":"Thavendiranathan P, Grant AD, Negishi T et al (2013) Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J\u00a0Am Coll Cardiol 61(1):77\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2012.09.035","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"4779_CR46","first-page":"279","volume":"30","author":"D Rea","year":"2016","unstructured":"Rea D, Coppola C, Barbieri A et al (2016) Strain analysis in the assessment of a\u00a0mouse model of cardiotoxicity due to chemotherapy: sample for preclinical research. In Vivo 30(3):279\u2013290","journal-title":"In Vivo"},{"issue":"2","key":"4779_CR47","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ultrasmedbio.2007.07.018","volume":"34","author":"RQ Migrino","year":"2008","unstructured":"Migrino RQ, Aggarwal D, Konorev E et al (2008) Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol 34(2):208\u2013214. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2007.07.018","journal-title":"Ultrasound Med Biol"},{"issue":"12","key":"4779_CR48","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.echo.2008.10.005","volume":"21","author":"R Jurcut","year":"2008","unstructured":"Jurcut R, Wildiers H, Ganame J et al (2008) Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J\u00a0Am Soc Echocardiogr 21(12):1283\u20131289. https:\/\/doi.org\/10.1016\/j.echo.2008.10.005","journal-title":"J Am Soc Echocardiogr"},{"issue":"12","key":"4779_CR49","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ejechocard\/jer187","volume":"12","author":"PW Stoodley","year":"2011","unstructured":"Stoodley PW, Richards DA, Hui R et al (2011) Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr 12(12):945\u2013952. https:\/\/doi.org\/10.1093\/ejechocard\/jer187","journal-title":"Eur J Echocardiogr"},{"issue":"2","key":"4779_CR50","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/ejechocard\/jep007","volume":"10","author":"SF Nagueh","year":"2009","unstructured":"Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10(2):165\u2013193. https:\/\/doi.org\/10.1093\/ejechocard\/jep007","journal-title":"Eur J Echocardiogr"},{"issue":"5","key":"4779_CR51","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/CAD.0b013e3283443704","volume":"22","author":"D Di Lisi","year":"2011","unstructured":"Di Lisi D, Bonura F, Macaione F et al (2011) Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. Anticancer Drugs 22(5):468\u2013472. https:\/\/doi.org\/10.1097\/CAD.0b013e3283443704","journal-title":"Anticancer Drugs"},{"issue":"3","key":"4779_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0160-5402(86)90046-X","volume":"16","author":"R Danesi","year":"1986","unstructured":"Danesi R, Del Tacca M, Soldani G (1986) Measurement of the S alpha T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. J\u00a0Pharmacol Methods 16(3):251\u2013259","journal-title":"J Pharmacol Methods"},{"issue":"1","key":"4779_CR53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/00005344-198401000-00028","volume":"6","author":"RA Jensen","year":"1984","unstructured":"Jensen RA, Acton EM, Peters JH (1984) Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J\u00a0Cardiovasc Pharmacol 6(1):186\u2013200","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"4779_CR54","doi-asserted-by":"publisher","first-page":"308","DOI":"10.31768\/2312-8852.2017.39(4):308-311","volume":"39","author":"I Skrypnyk","year":"2017","unstructured":"Skrypnyk I, Maslova G, Lymanets T, Gusachenko I (2017) L\u2011arginine is an effective medication for prevention of endothelial dysfunction, a\u00a0predictor of anthracycline cardiotoxicity in patients with acute leukemia. Exp Oncol 39(4):308\u2013311","journal-title":"Exp Oncol"},{"issue":"3","key":"4779_CR55","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/pbc.23012","volume":"57","author":"Y Shimomura","year":"2011","unstructured":"Shimomura Y, Baba R, Watanabe A et al (2011) Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 57(3):461\u2013466. https:\/\/doi.org\/10.1002\/pbc.23012","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"4779_CR56","first-page":"115","volume":"31","author":"JM Horacek","year":"2009","unstructured":"Horacek JM, Jakl M, Horackova J et al (2009) Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol 31(2):115\u2013117","journal-title":"Exp Oncol"},{"issue":"10","key":"4779_CR57","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.biopha.2004.12.003","volume":"59","author":"F Galetta","year":"2005","unstructured":"Galetta F, Franzoni F, Cervetti G et al (2005) Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 59(10):541\u2013544. https:\/\/doi.org\/10.1016\/j.biopha.2004.12.003","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"4779_CR58","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","volume":"6","author":"BC Drafts","year":"2013","unstructured":"Drafts BC, Twomley KM, D\u2019Agostino R Jr. et al (2013) Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6(8):877\u2013885. https:\/\/doi.org\/10.1016\/j.jcmg.2012.11.017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"4779_CR59","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/circimaging.112.973321","volume":"5","author":"H Sawaya","year":"2012","unstructured":"Sawaya H, Sebag IA, Plana JC et al (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596\u2013603. https:\/\/doi.org\/10.1161\/circimaging.112.973321","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"4779_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/0004563216650464","volume":"54","author":"M Jones","year":"2017","unstructured":"Jones M, O\u2019Gorman P, Kelly C et al (2017) High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Ann Clin Biochem 54(1):149\u2013157. https:\/\/doi.org\/10.1177\/0004563216650464","journal-title":"Ann Clin Biochem"},{"issue":"5","key":"4779_CR61","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.3892\/ol.2016.4424","volume":"11","author":"YD Wang","year":"2016","unstructured":"Wang YD, Chen SX, Ren LQ (2016) Serum B\u2011type natriuretic peptide levels as a\u00a0marker for anthracycline-induced cardiotoxicity. Oncol Lett 11(5):3483\u20133492. https:\/\/doi.org\/10.3892\/ol.2016.4424","journal-title":"Oncol Lett"},{"issue":"9a","key":"4779_CR62","doi-asserted-by":"publisher","first-page":"58b","DOI":"10.1016\/j.amjcard.2004.01.027","volume":"93","author":"H Krum","year":"2004","unstructured":"Krum H (2004) Tolerability of carvedilol in heart failure: clinical trials experience. Am J Cardiol 93(9a):58b\u201363b. https:\/\/doi.org\/10.1016\/j.amjcard.2004.01.027","journal-title":"Am J Cardiol"},{"issue":"3","key":"4779_CR63","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1253\/circj.CJ-11-0210","volume":"76","author":"M Kitakaze","year":"2012","unstructured":"Kitakaze M, Sarai N, Ando H et al (2012) Safety and tolerability of once-daily controlled-release carvedilol 10\u201380\u202fmg in Japanese patients with chronic heart failure. Circ\u00a0J 76(3):668\u2013674","journal-title":"Circ J"}],"container-title":["Herz"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-018-4779-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-018-4779-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T11:06:13Z","timestamp":1607339173000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-018-4779-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,17]]},"references-count":63,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4779"],"URL":"https:\/\/doi.org\/10.1007\/s00059-018-4779-y","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,17]]},"assertion":[{"value":"7 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"T.\u00a0Zhan, M.\u00a0Daniyal, J.\u00a0Li, and Y.\u00a0Mao declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}